Robin Avery, MD
Infectious Disease · Baltimore, MDNPI 1740244318
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,877 of the $2,975 with a category attached, or 96.7%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 96.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $2,416 and has fallen 95.9% since, to $98 in 2025.
Across 5 payments — averaging $594.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Kamada Ltd.$72
- Merck$26
Across 197 payments — averaging $6370.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$545K
- Merck$327K
- Shire North American Group Inc$204K
- Takeda Pharmaceuticals U.S.A., Inc.$162K
- Modernatx, Inc.$10K
- Qiagen, LLC$5K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$2,87797%
- Food & beverage$722%
- Education$261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,877 |
| Kamada Ltd. | 2 | $72 |
| Merck | 1 | $26 |
How this compares
$2,975 in reported general payments places this provider in the 75th percentile of 289 infectious disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 24 | $1,613 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $535 |
| Cefdinir | 22 | $410 |
| Azithromycin | 19 | $381 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $369 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 33 | $368 |
| Doxycycline Hyclate | 15 | $295 |
| Acyclovir | 20 | $264 |
| Fluconazole | 21 | $263 |
| Amoxicillin | 11 | $132 |
| Ciprofloxacin Hcl | 19 | $106 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Baltimore
- Robert RedfieldBaltimore$779K
- Luciana BorioBaltimore$671K
- Mark SulkowskiBaltimore$240K
- Jonathan ZenilmanBaltimore$202K
- Robert EdelmanBaltimore$125K
- Kjell WibergBaltimore$113K
- Christine DurandBaltimore$53K
- Myron LevineBaltimore$51K
- Robert BollingerBaltimore$50K
- Richard BergBaltimore$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.